ARAP1

ARAP1 Full Name

ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1

ARAP1 Introduction

Arf GTPase Activating Protein 1 (ARAP1) is a multidomain signaling protein and critical GTPase-activating enzyme that belongs to the ARAP family, serving as a central regulator of Arf and Rho GTPase signaling networks in mammalian cells. Encoded by the ARAP1 gene located on human chromosome 11q13.4, ARAP1 is ubiquitously expressed in human tissues with prominent enrichment in endothelial cells, epithelial cells, and metabolically active organs including the liver, kidney, and vascular tissues. As a dual-specificity GTPase activating protein, ARAP1 integrates Arf and Rho signaling cascades to coordinate intracellular membrane trafficking, cytoskeletal rearrangement, cell adhesion, and cellular migration. This versatile protein acts as a molecular switch that inactivates Arf6 and RhoA GTPases through its catalytic domains, precisely tuning dynamic cellular behaviors in response to extracellular stimuli. Accumulating molecular research demonstrates that ARAP1 plays vital roles in maintaining vascular homeostasis, tissue remodeling, and immune cell mobility. Dysregulated ARAP1 expression and functional defects are closely associated with vascular disorders, metabolic dysfunction, inflammatory progression, and tumor malignant transformation, establishing ARAP1 as a key regulatory gene and clinically relevant biomarker for multiple human diseases.

Figure 1. Schematic structure of ARAP1.

Structural Characteristics and Molecular Mechanism of ARAP1
ARAP1 features a complex multi-domain structural architecture that enables its dual GTPase regulatory activity and diverse protein interaction capabilities. The protein contains a conserved Arf GAP domain responsible for catalyzing GTP hydrolysis on Arf family GTPases, primarily Arf6, thereby converting active GTP-bound Arf6 into its inactive GDP-bound state. Additionally, ARAP1 harbors a functional Rho GAP domain that targets RhoA signaling, allowing simultaneous modulation of two core cytoskeletal regulatory pathways. Complementing its catalytic domains, ARAP1 possesses multiple ankyrin repeat motifs, PH domains, and zinc finger domains that mediate membrane lipid binding, subcellular localization, and interactions with various scaffold and signaling proteins. These structural features allow ARAP1 to dynamically localize to the plasma membrane and endosomal compartments during cellular activation. Through coordinated domain functions, ARAP1 links membrane lipid signaling to GTPase inactivation, forming a precise molecular mechanism that controls vesicle trafficking, membrane shaping, and actin cytoskeleton reorganization in living cells.

Clinical Significance: Type 2 Diabetes and Cancer
ARAP1 has emerged as an important susceptibility gene for type 2 diabetes mellitus (T2DM) through genome-wide association studies (GWAS). Multiple independent single nucleotide polymorphisms (SNPs) in the ARAP1 locus, including rs1552224, rs11603334, rs472165, rs10882272, and rs11600791, are strongly associated with increased risk of T2DM across diverse ethnic populations. These risk variants are located in an intronic region of ARAP1 and are associated with reduced ARAP1 expression in pancreatic islets and other metabolic tissues. The mechanism linking ARAP1 dysfunction to T2DM involves impaired insulin secretion from pancreatic beta-cells and reduced insulin sensitivity in peripheral tissues. In pancreatic beta-cells, ARAP1 regulates insulin granule trafficking and exocytosis, and reduced ARAP1 expression impairs glucose-stimulated insulin secretion. In insulin-sensitive tissues (adipose tissue, skeletal muscle, liver), ARAP1 regulates GLUT4 trafficking and insulin signaling. Individuals carrying ARAP1 risk alleles have reduced insulin secretion and increased insulin resistance, contributing to hyperglycemia and T2DM progression. Beyond T2DM, ARAP1 has been implicated in cancer. The ARAP1 gene is located at 11q13.4, a region that is frequently amplified in breast cancer, head and neck squamous cell carcinoma (HNSCC), esophageal cancer, and lung cancer. ARAP1 is overexpressed in these cancers due to gene amplification, and high ARAP1 expression correlates with advanced tumor stage, lymph node metastasis, and poor patient survival. ARAP1 promotes cancer cell proliferation, migration, and invasion by activating Rac1 and promoting the epithelial-mesenchymal transition (EMT). ARAP1 also contributes to chemoresistance by promoting DNA repair and cell survival pathways. Knockdown of ARAP1 in cancer cell lines suppresses tumor growth and metastasis in mouse xenograft models, suggesting that ARAP1 is a potential therapeutic target.

Alternate Names for ARAP1

ARAP1; ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1; centaurin, delta 2 , CENTD2; arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 1; cnt-d2; centaurin-delta-2; centaurin, delta 2; ARF-GAP, RHO-GAP, ankyrin repeat, and pleckstrin homology domains-containing protein 1; CENTD2; KIAA0782